Aseptic compounding of cabazitaxel injection concentrate begins with dissolution of the crystalline API in polysorbate 80 under a nitrogen overlay rather than in aqueous media, because the free base is practically insoluble in water. The 60 mg/1.5 mL single-dose format places the product within a cytotoxic hazardous-drug containment loop: compounding vessels are situated in an ISO 14644-1:2015 Class 5 isolator or closed restricted-access barrier system, and all transfer operations use single-use closed assemblies to reduce operator exposure. The API is charged into a jacketed stainless steel vessel at controlled room temperature, typically 15–25°C, and mixed until visual clarity is confirmed; undissolved crystalline cabazitaxel would otherwise blind the downstream sterilising-grade filter and reduce dose delivery. A 0.22 µm PVDF or polyethersulfone sterilising-grade membrane is selected on the basis of polysorbate 80 compatibility, and filter integrity is verified by bubble point or diffusive flow measurement before and after filtration in accordance with 21 CFR 211.113 and EU GMP Annex 1 requirements. Pre-filtration bioburden is maintained below 10 CFU/100 mL to justify the absence of terminal sterilisation; cabazitaxel is thermally labile and cannot be autoclaved without measurable degradation of the taxane nucleus. Filling into Type I glass vials proceeds on a piston or peristaltic filling line under first-air protection, and the filled vials are stoppered, capped, and subjected to 100% visual inspection under USP <790> conditions. Release testing includes USP <71> sterility, USP <85> bacterial endotoxins, USP <788> particulate matter, and assay of cabazitaxel and polysorbate 80 degradation products. The principal process failure mode is not microbial contamination but precipitation of cabazitaxel at the filter/vial interface when the vessel temperature falls or when residual water enters the compounding line; hence, the line is dried and the surfactant moisture content is limited to a defined specification before batching.

Why Does the Injection Concentrate Demand Surfactant-Mediated Dilution Before the Infusion Bag Transfer?

The requirement for surfactant-mediated solubilisation arises from the practical insolubility of cabazitaxel in aqueous media; direct addition of the polysorbate 80 concentrate to 0.9% sodium chloride or 5% dextrose without the manufacturer-supplied ethanol-water intermediate diluent produces localised precipitation and visible particles. In hospital pharmacy practice, manipulation is performed inside an ISO Class 5 biological safety cabinet or compounding aseptic isolator under USP <797> hazardous drug provisions, with closed-system transfer devices to limit aerosol and surface contamination. The concentrate vial is first diluted with the entire supplied diluent containing 13% ethanol in water to produce a clear intermediate solution, which is then transferred into a 250 mL non-PVC infusion bag of 0.9% sodium chloride or 5% dextrose. The final admixture is administered through an in-line 0.22 µm filter over 1 hour; the filter is not optional because it retains any precipitate formed by inadvertent handling errors and protects the patient from particulate load. In-use stability of the final dilution is constrained by both chemical degradation and microbial risk; published manufacturer stability data for the reference product assign the final infusion a maximum hold of 8 hours at 15–30°C after preparation, or 48 hours under refrigeration at 2–8°C when the product is held under aseptic conditions. The admixture must not be frozen, shaken vigorously, or combined with other medicinal products in the same infusion container. Polysorbate 80 present in the formulation is known to extract di(2-ethylhexyl) phthalate from flexible PVC; therefore, non-PVC or polyolefin containers and DEHP-free administration sets are specified. The principal operational boundary is the narrow window between precipitation and degradation: under-dilution causes cabazitaxel to recrystallise, while prolonged storage of the final admixture increases oxidative degradation of polysorbate 80 and generates sub-visible particulates that may not be detected by ordinary visual inspection.

When cabazitaxel is evaluated as an oral tablet candidate, the formulation problem shifts from sterility assurance to maintaining molecular dispersion during compression and storage, because cabazitaxel has no approved oral indication and clinically useful oral bioavailability is not established. The molecule is a CYP3A4 substrate and a P-glycoprotein efflux substrate; any oral solid-dosage programme must therefore combine an amorphous solubility-enhanced intermediate with a defined absorption-window strategy, otherwise gut-wall efflux and hepatic first-pass metabolism limit systemic exposure. Hot-melt extrusion with a polymer such as copovidone or hypromellose acetate succinate is the preferred route for producing a glass solution at laboratory to pilot scale. Barrel temperature profiles are selected only after differential scanning calorimetry and thermogravimetric analysis establish the API degradation onset; if the degradation onset is below the polymer processing range, the formulation is shifted to wet or dry granulation of a pre-formed amorphous dispersion rather than direct extrusion. The extrudate is milled to a particle-size distribution compatible with tablet compression, blended with microcrystalline cellulose, crospovidone, colloidal silicon dioxide, and sodium stearyl fumarate, and compressed on a rotary tablet press equipped with force feeders. Content uniformity is governed by USP <905>, dissolution by USP <711> in biorelevant media, and residual polymer degradation products by a stability-indicating HPLC method. The critical process boundaries are the glass transition temperature of the dispersion, which must remain above the compression and storage temperatures by a sufficient margin to prevent sintering and recrystallisation, and the tablet hardness, which must be high enough to resist chipping during coating but low enough to avoid delaying disintegration in the intestinal lumen. Because cabazitaxel is cytotoxic, dry-binder containment and wash-in-place cycles on the tablet press are defined using occupational exposure limits derived from the compound’s permissible daily exposure; this often forces single-product suites or dedicated contact parts for research batches.

Capsule Filling from Spray-Dried Amorphous Cabazitaxel Dispersions

Unlike the injectable concentrate, a spray-dried amorphous dispersion for capsule filling operates within a solid-state stability envelope defined by residual solvent, moisture uptake, and glass transition temperature. Cabazitaxel is spray-dried from a solvent system such as acetone/water or dichloromethane/ethanol with HPMCAS or copovidone to generate a high-surface-area amorphous intermediate; the outlet temperature and atomisation gas flow are adjusted to keep the powder below its critical moisture content, because adsorbed water plasticises the amorphous phase and accelerates recrystallisation. Residual solvent is controlled by secondary vacuum drying and measured by headspace gas chromatography under USP <467>, with acceptance limits derived from ICH Q3C for the actual solvents used. The dried dispersion is filled into hard hydroxypropyl methylcellulose capsules on a dosator or tamping-pin machine inside a controlled dry environment; relative humidity is held at the low level required to prevent deliquescence of the dispersion and to maintain adequate powder flow. Fill weight uniformity is verified by USP <905>, dissolution by USP <711>, and degradation products by a stability-indicating method. A major process failure mode is electrostatic charging of the amorphous powder, which causes sticking to machine surfaces and inconsistent tamping-pin compression; this is mitigated by grounding, humidity control, and the addition of glidants such as fumed silica at levels that do not compromise dissolution. The operational boundary for this dosage form is not chemical instability alone but the trade-off between milling and flow: fine milling increases dissolution surface area but reduces bulk density and capsule fillability, so the particle-size distribution is titrated against both USP <711> release profiles and capsule fill-weight capability. Cabazitaxel remains a low-dose cytotoxic compound in this setting; capsule filling therefore requires dedicated containment, and empty capsule shells and waste powder are treated as hazardous waste according to site-specific cytotoxic disposal procedures.

Wet Granulation Introduces a Recrystallisation Risk That Roller Compaction Controls

Often, wet granulation is requested in early oral prototype work to improve content uniformity, yet it introduces a recrystallisation risk for cabazitaxel amorphous dispersions. The granulation fluid is selected to minimise water activity: anhydrous ethanol or a hydroalcoholic mixture with a binder such as povidone is used when the dispersion is water-sensitive, while water is permitted only when the amorphous stabiliser contains a hydrophobic grade of HPMCAS that imparts adequate moisture resistance. A high-shear granulator fitted with jacketed temperature control and vacuum capability can shorten wet massing time; the fluid-bed drying inlet temperature is maintained below the recrystallisation onset as determined by modulated differential scanning calorimetry. Sieved granules are compressed after blending with extragranular disintegrant and lubricant; the tablet cores are film-coated to prevent light and moisture ingress. Batch-to-batch variance is dominated by granule moisture at discharge and by the proportion of fines, both of which affect flow, die filling, and content uniformity. Roller compaction is preferred over wet granulation when the dispersion has a narrow processing window between glass transition and degradation; dry granulation avoids solvent exposure and allows direct control of ribbon density as a predictor of tablet tensile strength. Published data for cabazitaxel-specific wet granulation conditions are limited because the compound has no commercial oral form; therefore, process parameters must be generated from batch-scale feasibility runs with the selected dispersion intermediate rather than transferred from injectable manufacturing.

Within a contract manufacturing transfer of cabazitaxel-containing tablet, capsule, granule, or injectable lines, the receiving site’s primary obligation is not formulation redesign but verification that existing unit operations remain within the registered control strategy. Cleaning validation for a cytotoxic taxane requires swab and rinse sampling with acceptance limits derived from the health-based exposure limit, and analytical methods must be validated for recovery from stainless steel, polymer gaskets, and curtain surfaces. Injectable transfer additionally requires aseptic process simulation with media fills at a frequency and scale defined by EU GMP Annex 1 and 21 CFR 211.63; oral solid transfer requires demonstration of blend uniformity, content uniformity, and dissolution equivalence against the originator batch. Equipment differences such as granulator bowl geometry, tablet press turret speed, or capsule filling nozzle diameter shift the shear history of the powder and therefore the dissolution surface area; this is addressed by a risk assessment under ICH Q9 and by bracketing the process parameters in the transfer protocol. The container closure system for injection is tested for integrity by dye ingress or vacuum decay under USP <1207>; oral solid packages are tested for moisture ingress under USP <671>. The receiving site must also verify that the cabazitaxel API retains its polymorphic form after milling or high-shear processing; X-ray powder diffraction is used to confirm absence of crystalline peak growth in amorphous intermediates, and thermogravimetric analysis provides a moisture correction for assay. All analytical methods transferred for cabazitaxel release and stability are validated according to ICH Q2 and executed under 21 CFR 211.194. The most common transfer failure is not chemical degradation but residual API carryover into non-cabazitaxel products; therefore, separate campaigns, dedicated disposable equipment for the injectable line, and maximum campaign length are specified before the first engineering batch.